Entrectinib

361 interactions 392 cited references

Also sold as: Rozlytrek Rozlytrek®

About Entrectinib

Entrectinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. It is also used to treat certain types of solid tumors in adults and children 12 years of age and older that cannot be treated by surgery or that has spread to other parts of the body… Read the full Entrectinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Rubella Virus Vaccine, Live Piperaquine Posaconazole Saquinavir Ketoconazole Topical Pimozide

29 Contraindicated 325 Major 7 Moderate

All (361) Contraindicated (29) Major (325) Moderate (7)

Major

Entrectinib Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Entrectinib Ensartinib Increased ensartinib exposure Details Entrectinib Enzalutamide Xtandi Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Eribulin Halaven An increased risk of QT interval prolongation Details Entrectinib Erythromycin Erythrocin Stearate Increased entrectinib exposure, an increased frequency or severity of adverse reactions including increased risk of cardiac arrhyt... Details Entrectinib Escitalopram Lexapro An increased risk of QT interval prolongation Details Entrectinib Etrasimod Velsipity Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Entrectinib Etravirine Intelence Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Famotidine Calmicid An increased risk of QT interval prolongation Details Entrectinib Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Entrectinib Felbamate Felbatol An increased risk of QT interval prolongation Details Entrectinib Fexinidazole Increased exposure of CYP3A4 substrate; increased risk of QT interval prolongation and arrhythmias Details Entrectinib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Entrectinib Fingolimod Gilenya An increased risk of QT interval prolongation Details Entrectinib Flecainide Tambocor® An increased risk of QT interval prolongation Details Entrectinib Fluoxetine RECONCILE An increased risk of QT interval prolongation Details Entrectinib Fluvoxamine Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Formoterol Perforomist An increased risk of QT interval prolongation Details Entrectinib Fosamprenavir Lexiva Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Foscarnet Foscavir An increased risk of QT interval prolongation Details Entrectinib Fosfomycin Contepo An increased risk of QT interval prolongation Details Entrectinib Fosnetupitant Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Fosphenytoin Cerebyx Reduced entrectinib exposure and efficacy and an increased risk of QT interval prolongation Details Entrectinib Fostemsavir Rukobia Increased risk of torsade de pointes Details Entrectinib Galantamine Razadyne An increased risk of QT interval prolongation Details Entrectinib Gatifloxacin Zymaxid An increased risk of QT interval prolongation Details Entrectinib Gemifloxacin Factive An increased risk of QT interval prolongation Details Entrectinib Gepirone Exxua An increased risk of QT interval prolongation and cardiac arrhythmias Details Entrectinib Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure and an increased risk of QT interval prolongation Details Entrectinib Givinostat Duvyzat Increased CYP3A4 substrate exposure, an increased risk of CYP3A4 substrate-related adverse effects and an increased risk of QT int... Details Entrectinib Glasdegib Daurismo An increased risk of QT interval prolongation Details Entrectinib Gonadorelin An increased risk of QT interval prolongation Details Entrectinib Goserelin An increased risk of QT interval prolongation Details Entrectinib Granisetron An increased risk of QT interval prolongation Details Entrectinib Halofantrine An increased risk of QT interval prolongation Details Entrectinib Haloperidol Increased haloperidol exposure, an increased risk of haloperidol-related adverse events and an increased risk of QT interval prolo... Details Entrectinib Histrelin Supprelin An increased risk of QT interval prolongation Details Entrectinib Hydroquinidine An increased risk of QT interval prolongation Details Entrectinib Hydroxychloroquine Plaquenil An increased risk of QT interval prolongation Details Entrectinib Hydroxyzine An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.